Differentiation of MEFs: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
'''==Strains==''' Wild type (Tsc2 +/+) and Tsc2 -/- (p53−/−) MEFs | '''==Strains==''' Wild type (Tsc2 +/+) and Tsc2 -/- (p53−/−) MEFs | ||
'''==Source==''' DJ Kwiatkowski (Brigham and Women's Hospital, Boston, MA) | '''==Source==''' DJ Kwiatkowski (Brigham and Women's Hospital, Boston, MA) | ||
==Papers== | |||
• Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, et al. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells. Hum Mol Genet 11: 525–534. | • Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, et al. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells. Hum Mol Genet 11: 525–534. | ||
• Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223–1233. | • Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223–1233. | ||